Gernandt & Danielsson advises JPMorganChase in connection with the financing of ANI Pharmaceuticals’ offer for Egetis Therapeutics

On 5 November 2026, ANI Pharmaceuticals, Inc. announced a recommended public takeover offer to shareholders and holders of convertibles and warrants in Egetis Therapeutics AB. The total value of the offer amounts to approximately SEK 5,304 million, and the consideration payable under the offer is financed in part through debt financing provided by JPMorgan Chase Bank, N.A. Gernandt & Danielsson has advised JPMorganChase on Swedish law aspects in connection with the financing.

Gernandt & Danielsson advises JPMorganChase with a team consisting of partners Niclas Rockborn, Mikael Bolling and Daniel Sveen as well as associate Erik Schwartz.